Kyverna Therapeutics (KYTX) Stock Price, News & Analysis

Company Overview

Kyverna Therapeutics is a clinical-stage biotechnology company focused on developing cell therapies for autoimmune diseases. The company is working to apply chimeric antigen receptor T-cell (CAR T) technology, traditionally used in certain blood cancers, to conditions in which the immune system attacks the body’s own tissues.

Kyverna’s lead investigational product, KYV-101, is an autologous, fully human CD19-directed CAR T-cell therapy designed to eliminate B cells that contribute to autoimmune disease. The therapy is being evaluated in clinical studies involving severe autoimmune conditions, including systemic sclerosis, lupus nephritis, myasthenia gravis and multiple sclerosis. Kyverna is also developing additional candidates and capabilities through its cell therapy platform.

Founded in 2018, Kyverna Therapeutics is headquartered in Emeryville, California. Its clinical development activities have included sites in the United States and Europe. The company’s leadership has included Peter Maag as chief executive officer, with the organization focused on advancing potentially disease-modifying treatments for patients with serious autoimmune disorders.

Key Stats

• Today's Range: $6.75 to $6.95
• 50-Day Range: $6.81 to $8.95
• 52-Week Range: $5.30 to $13.67
• Volume: 826,210 shs
• Average Volume: 922,111 shs
• Market Capitalization: $422.99 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $29.00
• Consensus Rating: Moderate Buy

Kyverna Therapeutics Stock Analysis - MarketRank™

Kyverna Therapeutics scored higher than 45% of companies evaluated by MarketBeat, and ranked 612th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Kyverna Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 1 strong buy rating, 5 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Kyverna Therapeutics has a consensus price target of $29.00, representing about 319.4% upside from its current price of $6.92.

Amount of Analyst Coverage

Kyverna Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Kyverna Therapeutics are expected to decrease in the coming year, from ($2.70) to ($2.82) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Kyverna Therapeutics is -2.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Kyverna Therapeutics is -2.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Kyverna Therapeutics has a P/B Ratio of 1.80. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

17.20% of the float of Kyverna Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Kyverna Therapeutics has a short interest ratio ("days to cover") of 10.78, which indicates bearish sentiment.

Change versus previous month

Short interest in Kyverna Therapeutics has recently increased by 3.69%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Kyverna Therapeutics does not currently pay a dividend.

Dividend Growth

Kyverna Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 0.68

News Sentiment

Kyverna Therapeutics has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 12 news articles for Kyverna Therapeutics this week, compared to 4 articles on an average week.

Search Interest

12 people have searched for KYTX on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.

MarketBeat Follows

2 people have added Kyverna Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Kyverna Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

17.60% of the stock of Kyverna Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

18.08% of the stock of Kyverna Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 9/29/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:KYTX
• Previous Symbol: NASDAQ:KYTX
• CIK: 1994702
• Web: kyvernatx.com
• Phone: (510) 925-2492
• Fax: N/A
• Employees: 149
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Kyverna Therapeutics: $29.00
• High Price Target: $33.00
• Low Price Target: $25.00
• Potential Upside/Downside: +324.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.86
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.94)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$161.31 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -81.92%
• Return on Assets: -63.74%

Debt

• Debt-to-Equity Ratio: 0.15
• Current Ratio: 9.06
• Quick Ratio: 9.06

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.85 per share
• Price / Book: 1.78

Miscellaneous

• Outstanding Shares: 61,840,000
• Free Float: 50,959,000
• Market Cap: $422.99 million
• Optionable: Optionable
• Beta: 1.98